Can a CGM Help With Prediabetes? What It Can’t Do

Maybe, but mostly as a learning tool rather than a proven treatment. In adults with prediabetes, continuous glucose monitoring can show glucose-pattern differences compared with normoglycemia, yet the evidence still does not show that wearing a CGM prevents diabetes or improves long-term health outcomes.

That gap matters. If you are considering a CGM, the useful question is not “Does it work?” in the abstract, but “What can it realistically help me notice, and what can’t it prove?”

Can CGM distinguish prediabetes from normal glucose?

Yes, to a degree. A 2026 systematic review and meta-analysis in the Journal of diabetes science and technology pooled 16 studies involving 1657 people and found that participants with prediabetes had measurably different CGM patterns from those with normoglycemia.

Compared with normoglycemia, prediabetes was associated with higher glycemic variability and glucose exposure, and the same meta-analysis concluded that CGM-derived metrics can discriminate between prediabetes and normoglycemia.

That is the strongest positive finding here: CGM appears able to detect meaningful pattern differences. For a person with prediabetes, that may make glucose less abstract. You are not just hearing that your labs are borderline; you may be able to see when your glucose tends to run higher and how variable it is across the day.

But pattern detection is not the same thing as diagnosis, and it is not the same thing as better health.

Does CGM improve outcomes in adults with prediabetes?

We do not have good evidence yet that it does. A 2024 narrative review in the Journal of diabetes science and technology concluded that, for nonpregnant adults with prediabetes, there were no consensus guidelines or high-quality evidence to guide CGM goals and metrics.

That means there is still no well-established answer to questions many buyers assume are settled: What number should you aim for? Which spikes matter? How much variability is too much? Which CGM metric should guide action in prediabetes?

The same review suggested that glycemic variability measures, especially MAGE, may become more useful in the future. But that is still a developing idea, not a validated target for routine use.

There is also no evidence here that CGM use in people with prediabetes lowers the risk of diabetes, heart disease, or death. A review article aimed at people without diabetes reported that no randomized trial has shown CGM improves heart health, longevity, or other long-term outcomes in healthy adults, and that the small trials that do exist mostly lasted only weeks or months, according to Longevity Cities.

Do people change diet or exercise after seeing CGM data?

Possibly, but the evidence is thin for adults without diabetes and even thinner for prediabetes specifically. An analysis in Clinical Correlations said there is no large randomized controlled trial specifically testing how CGMs change diet and exercise in adults without diabetes.

That is a major limitation, because behavior change is the whole point for most consumers. If a CGM is not helping you make useful changes, it is mostly generating data.

The same analysis pointed to indirect evidence from type 2 diabetes: after 3 months, CGM users averaged 346 minutes of weekly exercise versus 235 minutes in people who used self-monitoring. But calorie intake, fat consumption, and cholesterol intake did not differ between the groups.

So the best-supported behavior signal is not “people eat better after seeing their glucose.” It is closer to “some people may move more,” and that evidence comes from type 2 diabetes, not prediabetes.

If you are interested in wearables more broadly, our guide to needle-free glucose monitors explains what different devices can and cannot verify.

How does the evidence in prediabetes compare with type 2 diabetes?

The evidence is much stronger in type 2 diabetes. A 2024 meta-analysis in Diabetologia reviewed 12 randomized controlled trials with 1248 participants and found that CGM improved HbA1c compared with self-monitoring of blood glucose, with a mean difference of -0.31%.

That is an outcome most people recognize and clinicians use. It does not automatically mean the same benefit carries over to prediabetes, but it shows the basic technology can help in a group where treatment targets are clearer and the research base is better.

For prediabetes, the evidence mostly shows differences in CGM metrics, not proven improvements in clinical outcomes. That is why it is a mistake to talk about CGM for prediabetes as if it has the same evidence base as CGM for established diabetes.

What can a CGM not tell you?

It cannot diagnose prediabetes or diabetes. Consumer CGMs are not meant to replace standard diagnostic tests such as fasting plasma glucose, HbA1c, or an oral glucose tolerance test, as summarized by Longevity Cities.

It also does not measure blood glucose directly. The National Institute of Diabetes and Digestive and Kidney Diseases explains that CGM sensors estimate glucose in the fluid between cells, not directly from the bloodstream.

A CGM also cannot tell you, by itself, whether a short-lived rise after a meal is dangerous, whether one food is “bad” in general, or whether reacting to every fluctuation is useful. In prediabetes, there are no consensus targets telling users which patterns deserve action and which are just normal variation.

And it cannot do much if it is worn sporadically. The NIDDK says the people who benefit most from CGM are those who use it every day or nearly every day. The same agency notes that devices differ: some are real-time and send data automatically, some require intermittent scans, and some are professional devices worn briefly and reviewed later with a clinician.

So when might a CGM be worth trying for prediabetes?

A CGM makes the most sense if your goal is education, not diagnosis and not guaranteed risk reduction. It may be useful if you want help spotting patterns you can respond to consistently, especially if seeing real-time data makes healthy habits more concrete.

It makes less sense if you expect it to answer every question about your metabolism, replace standard lab testing, or prove that you are avoiding future diabetes. Current evidence does not support those claims.

That distinction may sound narrow, but it is practical. A tool can be informative before it is fully validated as an outcome-improving intervention. The problem is when informative gets marketed as transformative.

What the evidence cannot tell us yet

The current research does not show that CGM use prevents diabetes, heart disease, or death in people with prediabetes. Most of the evidence in this area is about glucose patterns and short-term measurements rather than long-term clinical outcomes.

Behavior-change evidence is also limited. The available comparison suggesting more exercise comes from type 2 diabetes, not from a large randomized trial in adults without diabetes.

There is also little here on real-world barriers such as cost, adherence, or access in people with prediabetes specifically. Those practical issues matter, but they are not answered by the evidence summarized here.

FAQ

Can a CGM diagnose prediabetes?

No. Prediabetes and diabetes are diagnosed with standard tests such as fasting plasma glucose, HbA1c, or an oral glucose tolerance test, not with a consumer CGM.

Does CGM prove that someone with prediabetes will avoid diabetes?

No. Long-term studies are still needed, and there is no randomized trial showing CGM lowers diabetes incidence or improves other long-term outcomes in adults without diabetes.

Is there evidence that CGM can show abnormal glucose patterns in prediabetes?

Yes. A 2026 meta-analysis found that people with prediabetes had higher glycemic variability and glucose exposure than people with normoglycemia, and concluded that CGM-derived metrics can distinguish the groups.

Is the evidence stronger for type 2 diabetes than for prediabetes?

Yes. Type 2 diabetes has randomized-trial meta-analysis evidence showing improved HbA1c, while prediabetes still lacks consensus guidelines and high-quality evidence for CGM goals and metrics.

What this means for you

• CGM can reveal measurable glucose-pattern differences in prediabetes, but that does not prove better health outcomes.
• For prediabetes, the evidence base is still thin: there are no consensus guidelines or high-quality targets for routine CGM use.
• If CGM changes behavior, the clearest evidence so far comes from type 2 diabetes studies, not prediabetes studies.
• A CGM should not be treated as a diagnostic test for prediabetes or diabetes.
• If you do use a CGM, consistency matters; the NIDDK says people who benefit most use it every day or nearly every day.

Sources

• Could Adults Without Diabetes Benefit from Continuous Glucose Monitoring? – Clinical Correlations — clinicalcorrelations.org
• Continuous Glucose Monitoring – NIDDK — National Institute of Diabetes and Digestive and Kidney Diseases, 2025-10-03
• CGM for Non-Diabetics: Worth It? Normal Ranges, Cost 2026 — Longevity Cities, 2026-10-21
• Differences in Continuous Glucose Monitoring Metrics Between Prediabetes and Normoglycemia: A Systematic Review and Meta-Analysis. — Journal of diabetes science and technology, 2026
• Continuous Glucose Monitoring for Prediabetes: What Are the Best Metrics? — Journal of diabetes science and technology, 2024
• Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis. — Diabetologia, 2024

This article is for general education and is not medical advice, diagnosis or treatment. Do not start, stop or change medication or supplements based on it. Discuss personal health decisions with a qualified healthcare professional.